As the demand for specialized medications, particularly GLP-1s for obesity and diabetes, continues to rise, logistics companies are adapting their strategies to ensure proper storage and transportation.
UPS has invested $48 million in temperature-controlled facilities, anticipating a market for temperature-sensitive biologics to grow at an 8.3% compound annual growth rate, reaching approximately $39.1 billion by 2033. FedEx is also expanding its healthcare logistics capabilities, reporting nearly $10 billion in healthcare transportation revenue for fiscal year 2026.
Both companies emphasize the need for end-to-end visibility and reliability in their supply chains, as improper temperature management can compromise medication quality. C.H. Robinson has reported over $1 billion in healthcare logistics revenue, driven by the GLP-1 boom, while DHL plans to invest €2 billion in health logistics by 2030.
The increasing complexity of drug delivery, including short shelf lives and the need for precise timing, is creating competitive pressures on cold chain resources. Overall, the logistics sector is positioning itself to capitalize on the growing healthcare market, driven by innovations in temperature control and supply chain management